RA

Rakesh Ahuja

Biotech Investor/Therapeutics Analyst - Actively Looking for Biotech/Therapeutics Investment Analyst Roles

New York City Metropolitan Area

Overview 

Rakesh Ahuja is a Biotech Investor and Therapeutics Analyst with a strong track record in leading therapeutics analysis at a $500M Biotech Specialist Hedge Fund and serving as a Board Observer at Q32 Bio Inc. during a Series B investment. With a diverse background encompassing roles in equity research, investment banking, corporate finance, and private equity, Rakesh is actively seeking new opportunities in biotech/therapeutics investment analyst roles in the New York City Metropolitan Area.

Work Experience 

  • Biotech Executive Consultant

    2024 - Current

    Provide strategic support and advisory services to executives and managers in the following areas: -Market analysis and competitive intelligence -Investor Relations -Business and Corporate Development (licensing, mergers and acquisitions) Work broadly across therapeutics but have specialized knowledge in: I&I, Rare Disease, Gene Therapy, Primary Care, Neurology

  • Lead Therapeutics Analyst

    2019 - 2024

    Led investments across 20+ SMID-cap companies. Primary focus was Ph1 to Ph3 readout stage public companies but opportunistically in pre-clinical private companies as well. Broad therapeutics coverage with sub-specializations in: Immunology & Inflammation Gene Therapy Rare Disease Neurology Full Cycle Plug/Play Responsibilities: idea generation and company screening, clinical diligence (PK modeling, data benchmarking, KOL interviews), financial modeling (returns, dilution analysis, investment size), final recommendation to portfolio manager in PowerPoint presentation for approval, and point person for position monitoring/company engagement through divestment Investment Tools/Resources: Bloomberg, FDA/Clinicaltrials.gov, EvaluatePharma, Biocentury, UpToDate, Biomedtracker, PubMed, Guidepoint, Statistician etc.

  • Equity Research: Biotech and Pharmaceuticals

    2016 - 2018

    One of 2 person senior associate team to analyst Liav Abraham, Co-Head of Citi Global Healthcare. Covered Biotech and Spec Pharm: ACRS, AAAP, ALKS, AGN, DBVT, DERM, ENDP, HZNP, INSM, JAZZ, MYL, SGYP, TEVA, ZTS

Citigroup is a financial services holding company that provides various financial products and services.

Raised $12,950,000,000.00 from ValueAct Capital and Abu Dhabi Investment Authority.

  • Investment Banking: Biotech and Pharmaceuticals

    2015 - 2016

    Involved in all aspects of transactions including: M&A and financial modeling, participating in pitchbook presentations, roadshows, S-1 drafting sessions, and meetings with senior management Selected Sell-Side Mergers and Acquisitions Transaction Experience (Deals): MRUS IPO-$55M in May 2016 (closed after leaving firm) RVNC Follow On-$135M in Nov 2015 AQXP Follow On-$98M in September 2015 EGLT Follow On-$86M in July 2015

Guggenheim Digital Media is a financing and trading company which partners with those in real estate.

  • Corporate Finance and Advisory: Biotech and Pharmaceuticals

    2014 - 2015

    Served as the right-hand Gary Brewster, group head of life science advisory. Directed the efforts of analysts, constructed/reviewed industry specific financial models (e.g., risk adjusted product DCFs for the FDA approval process, structured deal analysis with regulatory milestones and revenue targets etc.), and delivered marketing presentations/pitches to win business across M&A Advisory, Capital Markets and Restructuring Selected Mergers and Acquisitions Transaction Experience (Fairness Opinions): Horizon Pharma plc acquisition of Hyperion Therapeutics for $1.1B in Mar 2015 Globus Medical acquisition of Branch Medical Group for $52.9M in Feb 2015

Houlihan Lokey is an investment bank that offers financial services.

  • Private Equity and Asset Management: Biotech and Generalist

    2009 - 2014

  • Yale Medical School Research Scientist: Neuro-Oncology - Van den Pol Lab

    2005 - 2008

    Etta S Chidsey Cancer Research Award: Studied the use of attenuated rhabodovirus strains with pharmacological management in the treatment of gliobastoma multiforme

  • UC-Berkeley Research Scientist: Immunology-Robey Lab

    2001 - 2005

    Contributing Author in Journal of Immunology Publication: CD226 Is Specifically Expressed on the Surface of Th1 Cells and Regulates Their Expansion and Effector Functions

  • Harvard Medical School Research Scientist: Pathophysiology of Multiple Sclerosis-Kuchroo Lab

    1998 - 2001

Articles About Rakesh

Relevant Websites